Effect of liver cirrhosis on the systemic availability of naltrexone in humans

Journal of Hepatology

Volumn 27, Issue 3, 1997, Pages 505-511

  Bertolotti, Marco ^a   Ferrari, Anna ^a   Vitale, Giovanni ^a   Stefani, Marina ^a   Trenti, Tommaso ^a   Loria, Paola ^a   Carubbi, Francesca ^a   Carulli, Nicola ^a   Sternieri, Emilio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

6 naltrexol; Liver cirrhosis; Naltrexone; Pharmacokinetics; Systemic availability

Indexed keywords

NALTREXONE;

ADULT; AGED; ARTICLE; CHOLESTASIS; CLINICAL ARTICLE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER METABOLISM; LIVER MICROSOME; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030767484     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80355-8     Document Type: Article

References (24)

1. Crabtree BL. Review of naltrexone, a long-acting opiate antagonist. Clin Pharm. 3:1984;273-280.
2. Gonzalez JP, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 35:1988;192-213.
3. Verebey K. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics. Willette RE, Barnett G. Narcotic Antagonists: Naltrexone Pharmacochemistry and Sustained-Release Preparations. 1981;147-158 US Department of Health and Human Services. NIDA Research Monograph 28.
4. Greenstein RA, Arndt IC, McLellan AT, O'Brien CP, Evans B. Naltrexone: a clinical perspective. J Clin Psychiatr. 45:1984;25-28.
5. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP. Effect of naltrexone on alcohol "highs" in alcoholics. Am J Psychiatr. 152:1995;613-615.
6. Wall ME, Brine DR, Perez-Reyes M. The metabolism of naltrexone in man. Willette RE, Barnett G. Narcotic Antagonists: Naltrexone Pharmacochemistry and Sustained-Released Preparations. 1981;105-131 US Department of Health and Human Services. NIDA Research Monograph 28.
7. Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC. Bioequivalence, dose-proportionality and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatr. 45:1984;15-19.
8. Cone EJ, Gorodetzky CW, Yeh SY. The urinary excretion profile of naltrexone and metabolites in man. Drug Metab Dispos. 2:1974;506-512.
9. Verebey K, Volavka J, Mule SJ, Resnick RB. Naltrexone: disposition, metabolism and effects after acute and chronic dosing. Clin Pharmacol Ther. 20:1976;315-328.
10. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. Br Med J. 297:1988;1501-1504.
11. Jones EA, Bergasa NV. The pruritus of cholestasis: from bile acids to opiate antagonists. Hepatology. 11:1990;884-887.
12. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology. 102:1992;544-549.
13. Wolfhagen FHJ, van Buuren HR, Vitale G, Bertolotti M, Sternieri E, Schalm SW. Oral naltrexone for cholestatic pruritus: a double-blind, placebo-controlled trial [abstract]. J Hepatol. 23:1995;86. suppl 1.
14. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:1973;646-649.
15. Zuccaro PG, Altieri I, Betto P, Pacifici R, Ricciariello G, Pini LA, et al. Determination of naltrexone and 6β-naltrexol in plasma by high performance liquid chromatography with coulometric detection. J Chromatogr. 567:1991;485-490.
16. Ferrari A, Bertolotti M, Trenti T, Vitale G, Stefani M, Sternieri E. Naltrexone and 6β-naltrexol concentration/time profile in the treatment of opiate dependence [abstract]. Can J Physiol Pharm. 72:1994;394. suppl 1.
17. Atkinson RL, Berke LK, Drake CR, Bibbs ML, Williams FL, Kaiser DL. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther. 38:1985;419-422.
18. Mitchell JE. Naltrexone and hepatotoxicity [letter]. Lancet. i:1986;1215.
19. Brahen LS, Capone TJ, Capone DM. Naltrexone: lack of effect of hepatic enzymes. J Clin Pharmacol. 28:1988;64-70.
20. Pini L-A, Ferretti C, Trenti T, Ferrari A, Sternieri E. Effects of long-term treatment with naltrexone on hepatic enzyme activity. Drug Metab Drug Interact. 9:1991;161-174.
21. Branch RA. Drugs as indicators of hepatic function. Hepatology. 2:1982;97-105.
22. Bircher J. Quantitative assessment of deranged hepatic function: a missed opportunity? Semin Liver Dis. 3:1983;275-284.
23. Renner E, Wietholtz H, Huguenin P, Arnaud MJ, Preisig R. Caffeine: a model compound for measuring liver function. Hepatology. 4:1984;38-46.
24. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 18:1975;377-390.